These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

566 related items for PubMed ID: 16033876

  • 21. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study.
    Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, Fillit H, Stefanick ML, Hendrix SL, Lewis CE, Masaki K, Coker LH, Women's Health Initiative Memory Study.
    JAMA; 2004 Jun 23; 291(24):2947-58. PubMed ID: 15213206
    [Abstract] [Full Text] [Related]

  • 22. Investigative models for determining hormone therapy-induced outcomes in brain: evidence in support of a healthy cell bias of estrogen action.
    Brinton RD.
    Ann N Y Acad Sci; 2005 Jun 23; 1052():57-74. PubMed ID: 16024751
    [Abstract] [Full Text] [Related]

  • 23. Abbreviated hormone replacement therapy trial answers some questions, raises new ones. The Women's Health Initiative is no longer testing the most widely prescribed estrogen and progestin combination--but the study's job is far from over.
    Harv Womens Health Watch; 2002 Oct 23; 10(2):2-4. PubMed ID: 12393317
    [No Abstract] [Full Text] [Related]

  • 24. Risk of cardiovascular disease in relation to the use of combined postmenopausal hormone therapy: detection bias and resolution of discrepant findings in two Women's Health Initiative studies.
    Shapiro S.
    Climacteric; 2006 Dec 23; 9(6):416-20. PubMed ID: 17085373
    [Abstract] [Full Text] [Related]

  • 25. The impact of the Women's Health Initiative on hormone replacement therapy in a Medicaid program.
    Hillman JJ, Zuckerman IH, Lee E.
    J Womens Health (Larchmt); 2004 Nov 23; 13(9):986-92. PubMed ID: 15665655
    [Abstract] [Full Text] [Related]

  • 26. Hormone replacement therapy and cardioprotection: what is good and what is bad for the cardiovascular system?
    Rosano GM, Vitale C, Fini M.
    Ann N Y Acad Sci; 2006 Dec 23; 1092():341-8. PubMed ID: 17308159
    [Abstract] [Full Text] [Related]

  • 27. Changes in women's use of hormones after the Women's Health Initiative estrogen and progestin trial by race, education, and income.
    Wei F, Miglioretti DL, Connelly MT, Andrade SE, Newton KM, Hartsfield CL, Chan KA, Buist DS.
    J Natl Cancer Inst Monogr; 2005 Dec 23; (35):106-12. PubMed ID: 16287895
    [Abstract] [Full Text] [Related]

  • 28. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease.
    Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, Speizer FE, Hennekens CH.
    N Engl J Med; 1996 Aug 15; 335(7):453-61. PubMed ID: 8672166
    [Abstract] [Full Text] [Related]

  • 29. Health risks outweigh benefits for combined estrogen plus progestin. Clinical trial stopped early in major study.
    American Medical Association.
    Ginecol Obstet Mex; 2002 Aug 15; 70():411-2. PubMed ID: 12449905
    [No Abstract] [Full Text] [Related]

  • 30. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.
    Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner RL, Manson JE, Gass ML, Stefanick ML, Lane DS, Hays J, Johnson KC, Coker LH, Dailey M, Bowen D, WHIMS Investigators.
    JAMA; 2003 May 28; 289(20):2663-72. PubMed ID: 12771113
    [Abstract] [Full Text] [Related]

  • 31. Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women's Health Initiative Randomized Trial.
    Chlebowski RT, Anderson GL, Sarto GE, Haque R, Runowicz CD, Aragaki AK, Thomson CA, Howard BV, Wactawski-Wende J, Chen C, Rohan TE, Simon MS, Reed SD, Manson JE.
    J Natl Cancer Inst; 2016 Mar 28; 108(3):. PubMed ID: 26668177
    [Abstract] [Full Text] [Related]

  • 32. Effects of hormone therapy on soluble cell adhesion molecules in postmenopausal women with coronary artery disease.
    Yeboah J, Klein K, Brosnihan B, Reboussin D, Herrington DM.
    Menopause; 2008 Mar 28; 15(6):1060-4. PubMed ID: 18521047
    [Abstract] [Full Text] [Related]

  • 33. Invited Commentary: Hormone therapy risks and benefits--The Women's Health Initiative findings and the postmenopausal estrogen timing hypothesis.
    Banks E, Canfell K.
    Am J Epidemiol; 2009 Jul 01; 170(1):24-8. PubMed ID: 19468078
    [Abstract] [Full Text] [Related]

  • 34. KEEPS: The Kronos Early Estrogen Prevention Study.
    Harman SM, Brinton EA, Cedars M, Lobo R, Manson JE, Merriam GR, Miller VM, Naftolin F, Santoro N.
    Climacteric; 2005 Mar 01; 8(1):3-12. PubMed ID: 15804727
    [Abstract] [Full Text] [Related]

  • 35. Effect of hormone therapy on mortality rates among women with heart failure and coronary artery disease.
    Bibbins-Domingo K, Lin F, Vittinghoff E, Barrett-Connor E, Hulley SB, Grady D, Shlipak MG.
    Am J Cardiol; 2005 Jan 15; 95(2):289-91. PubMed ID: 15642574
    [Abstract] [Full Text] [Related]

  • 36. A clinician's review of the WHI-related literature.
    Speroff L.
    Int J Fertil Womens Med; 2004 Jan 15; 49(6):252-67. PubMed ID: 15751264
    [Abstract] [Full Text] [Related]

  • 37. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation.
    Grodstein F, Manson JE, Stampfer MJ.
    J Womens Health (Larchmt); 2006 Jan 15; 15(1):35-44. PubMed ID: 16417416
    [Abstract] [Full Text] [Related]

  • 38. [Prevention of coronary heart disease by early postmenopausal hormone therapy: new supporting data].
    Gaspard U.
    J Gynecol Obstet Biol Reprod (Paris); 2008 Jun 15; 37(4):340-5. PubMed ID: 18249506
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.